other material
confidence high
sentiment positive
materiality 0.55
FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones
XOMA Royalty Corp
- FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.
- XOMA is entitled to a mid-single digit royalty on commercial sales of MIPLYFFA.
- XOMA may receive up to $52.6 million (net) in milestone payments from Zevra.
- MIPLYFFA is the sixth commercial asset in XOMA's royalty and milestone portfolio.